Drugs / anti-GD2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03242603 | Oct 2017 → Aug 2019 | neuroblastoma | National University Hospital, Singapore | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-GD2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03242603 ↗ |
| Known as | ch14.18/CHO | “combination with anti-GD2 (ch14.18/CHO)” NCT03242603 ↗ |
| Action | Deplete | “The anti-GD2 antibody mediates neuroblastoma cell killing” NCT03242603 ↗ |